What is William Blair's Estimate for Biogen Q2 Earnings?

Biogen Inc. (NASDAQ:BIIB - Free Report) - Investment analysts at William Blair dropped their Q2 2025 EPS estimates for shares of Biogen in a report released on Tuesday, May 27th. William Blair analyst M. Minter now forecasts that the biotechnology company will post earnings of $4.09 per share for the quarter, down from their prior estimate of $4.34. The consensus estimate for Biogen's current full-year earnings is $15.83 per share. William Blair also issued estimates for Biogen's FY2025 earnings at $14.68 EPS.

A number of other equities research analysts also recently weighed in on the stock. Citigroup lowered their target price on shares of Biogen from $160.00 to $145.00 and set a "neutral" rating on the stock in a research note on Thursday, February 13th. The Goldman Sachs Group decreased their price target on shares of Biogen from $219.00 to $197.00 and set a "buy" rating on the stock in a research note on Wednesday, April 23rd. Scotiabank decreased their price target on shares of Biogen from $244.00 to $224.00 and set a "sector outperform" rating on the stock in a research note on Thursday, February 13th. HC Wainwright decreased their price target on shares of Biogen from $241.00 to $187.00 and set a "buy" rating on the stock in a research note on Friday, May 2nd. Finally, JPMorgan Chase & Co. decreased their price target on shares of Biogen from $185.00 to $175.00 and set a "neutral" rating on the stock in a research note on Monday, May 5th. Twenty investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $191.30.

Biogen Stock Performance

NASDAQ BIIB traded up $2.72 during trading on Friday, hitting $133.86. 570,797 shares of the company's stock traded hands, compared to its average volume of 1,410,361. Biogen has a 12-month low of $110.04 and a 12-month high of $238.00. The stock has a market capitalization of $19.61 billion, a price-to-earnings ratio of 11.96, a PEG ratio of 1.51 and a beta of 0.12. The company has a debt-to-equity ratio of 0.27, a quick ratio of 0.90 and a current ratio of 1.35. The business has a 50 day moving average of $123.21 and a 200-day moving average of $138.87.

Biogen (NASDAQ:BIIB - Get Free Report) last posted its earnings results on Thursday, May 1st. The biotechnology company reported $3.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.26 by ($0.24). Biogen had a return on equity of 14.98% and a net margin of 16.87%. The firm had revenue of $2.43 billion during the quarter, compared to the consensus estimate of $2.25 billion. During the same quarter in the previous year, the company earned $3.67 EPS. The business's revenue was up 6.2% compared to the same quarter last year.

Insider Buying and Selling at Biogen

In other Biogen news, Director Stephen A. Sherwin sold 8,760 shares of the firm's stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $150.02, for a total value of $1,314,175.20. Following the completion of the sale, the director now owns 11,318 shares of the company's stock, valued at approximately $1,697,926.36. This trade represents a 43.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.16% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Signaturefd LLC raised its stake in shares of Biogen by 3.5% during the 4th quarter. Signaturefd LLC now owns 2,092 shares of the biotechnology company's stock worth $320,000 after buying an additional 71 shares during the period. Quent Capital LLC raised its stake in Biogen by 31.9% in the 4th quarter. Quent Capital LLC now owns 298 shares of the biotechnology company's stock valued at $46,000 after purchasing an additional 72 shares during the last quarter. Principal Securities Inc. raised its stake in Biogen by 30.1% in the 4th quarter. Principal Securities Inc. now owns 337 shares of the biotechnology company's stock valued at $52,000 after purchasing an additional 78 shares during the last quarter. Israel Discount Bank of New York raised its stake in Biogen by 6.2% in the 4th quarter. Israel Discount Bank of New York now owns 1,405 shares of the biotechnology company's stock valued at $215,000 after purchasing an additional 82 shares during the last quarter. Finally, Deseret Mutual Benefit Administrators raised its stake in Biogen by 5.7% in the 4th quarter. Deseret Mutual Benefit Administrators now owns 1,612 shares of the biotechnology company's stock valued at $247,000 after purchasing an additional 87 shares during the last quarter. 87.93% of the stock is owned by institutional investors and hedge funds.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.